Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 1, 2014, Pages 43-52

  Florholmen, Jon ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Crohn's disease; Intestinal epithelial barrier; Natural course; Tumor necrosis factor ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

GASTROINTESTINAL ENDOSCOPY; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84919455017     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.977943     Document Type: Review

References (98)

1. Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;4:322-37.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-17.
3. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-42.
4. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
6. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
7. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
8. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
9. Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther 2014;40:903-16.
10. Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8.
11. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353: 1912-25.
12. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
13. Kawalec P, Mikrut A, Wis̈niewska N, Pilc A. Tumor necrosis factor-a antibodies (infliximab, adalimumab and certolizu-mab) in Crohn's disease: systematic review and meta-anal-ysis. Arch Med Sci 2013;9:765-79.
14. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther 2014;14:583-600.
15. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301.
16. Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34: 113-24.
17. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46.
18. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44.
19. Rutgeerts P, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileoco-lonic Crohn's disease-first results of the EXTEND Trial. Gastroenterology 2009;136:A-116.
20. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799-809.
21. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
22. Karrasch T, Jobin C. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z Gastroenterol 2009;47:1221-9.
23. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013;19:429-44.
24. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroen-terol Rep 2013;15:315.
25. Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19:7552-60.
26. Rismo R, Olsen T, Cui G, Paulssen EJ, Christiansen I, Johnsen K, et al. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Scand J Gastroenterol 2013;48:311-19.
27. Parlato M, Yeretssian G. NOD-like receptors in intestinal homeostasis and epithelial tissue repair. Int J Mol Sci 2014; 15:9594-627.
28. Baum B, Georgiou M. Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling. J Cell Biol 2011;192:907-17.
29. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97-107.
30. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, et al. Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014;8:1147-65.
31. Bonyadi M, Abdolmohammadi R, Jahanafrooz Z, Somy MH, Khoshbaten M. TNF-alpha gene polymorphisms in Iranian Azari Turkish patients with inflammatory bowel diseases. Saudi J Gastroenterol 2014;20:108-12.
32. Shih DQ, Targan SR. Insights into IBD Pathogenesis. Curr Gastroenterol Rep 2009;11:473-80.
33. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol 2014;26:237-45.
34. Wei J, Feng J. Signaling pathways associated with inflammatory bowel disease. Recent Pat Inflamm Alergy Drug Discov 2010;4:105-17.
35. Kaser A, Zeissig S, Blumberg RS. Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig Dis 2010;28:395-405.
36. Olsen T, Goll R, Cui G, Husebekk A, Vonen B, Birketvedt GS, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol 2007;42: 1312-20.
37. Leppkes M, Roulis M, Neurath MF, Kollias G, Becker C. Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation. Int Immunol 2014;26:509-15.
38. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409-19.
39. Green DR, Oberst A, Dillon CP, Weinlich R, Salvesen GS. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol Cell 2011;44:9-16.
40. Corredor J, Yan F, Shen CC, Tong W, John SK, Wilson G, et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol 2003;284:C953-61.
41. Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002;122:134-44.
42. Hilliard VC, Frey MR, Dempsey PJ, Peek RM Jr, Polk DB. TNF-alpha converting enzyme-mediated ErbB4 transactiva-tion by TNF promotes colonic epithelial cell survival. Am J Physiol Gastrointest Liver Physiol 2011;301:G338-46.
43. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013;152:25-38.
44. Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: what does it mean? World J Gastroenterol 2013;19:7552-60.
45. Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, et al. Scientific Committee of the European Crohn's and Colitis Organization. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011;5:484-98.
46. Pagnini C, Menasci F, Festa S, Rizzatti G, Delle Fave G. "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Patho-physiol 2014;5:54-62.
47. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
48. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
49. Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8.
50. Schroeder KW, Tremaine WJ. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
51. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
52. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42.
53. Korelitz BI, Sommers SC. Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol 1984;6:123-7.
54. Korelitz BI. Mucosal healing as an index of colitis activity: back to histological healing for future indices. Inflamm Bowel Dis 2010;16:1628-30.
55. Hartmann F, Stein J; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010;32:368-76.
56. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, et al. International Salofalk OD Study Group. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009;58:233-40.
57. Bressenot A, Geboes K, Vignaud JM, Guéant JL, Peyrin-Biroulet L. Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1745-52.
58. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014;12:929-34.
59. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46.
60. Isaacs KL. How rapidly should remission be achieved? Dig Dis 2010;28:548-55.
61. Gheorghe C, Cotruta B, Iacob R, Becheanu G, Dumbrava M, Gheorghe L. Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. Gastrointestin Liver Dis 2011;20:423-6.
62. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132: 763-86.
63. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004;19:308-15.
64. Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Inflix-imab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727-35.
65. Rismo R, Olsen T, Ciu G, Paulssen EJ, Christiansen I, Florholmen J, et al. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 2012;47:1200-10.
66. Karlsson M, Linton L, Lampinen M, Karlén P, Glise H, Befrits R, et al. Naïve T cells correlate with mucosal healing in patients with inflammatory bowel disease. Scand J Gastro-enterol 2014;49:66-74.
67. Grundström J, Linton L, Thunberg S, Forsslund H, Janczewska I, Befrits R, et al. Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease. Clin Exp Immunol 2012;169:137-47.
68. D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. Future directions in inflammatory bowel disease management. J Crohns Colitis 2014;8:726-34.
69. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:579-94.
70. Noth R, Stüber E, Häsler R, Nikolaus S, Kühbacher T, Hampe J, et al. Anti-TNF-alpha antibodies improve intestinal barrier function in Crohn's disease. J Crohns Colitis 2012;6:464-9.
71. Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2013;304:G970-9.
72. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
73. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
74. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11.
75. Adalimumab in the treatment of moderate-to-severe ulcer-ative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y) 2013;9:317-20.
76. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109:1771-80.
77. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847-57.
78. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22.
79. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. IBSEN Study Group. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40.
80. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
81. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42.
82. Baert F, Moortgat L, VanAssche G, Caenepeel P, Vergauwe P, DeVos M, et al. BelgianInflammatoryBowelDiseaseResearch Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8.
83. Crombé V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G, Lerebours E, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: apopulation-basedstudy.InflammBowelDis2011;17:2144-52.
84. Travis SPL, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, et al. Reviewarticle:definingremission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24.
85. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105.
86. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroen-terol Rep 2013;15:0315-17.
87. Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014;20:4980-6.
88. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerativecolitis. Gastroenterology 2011;141:1194-201.
89. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immuno-suppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
90. National Institute for Health and Clinical Excellence. Infliximab (review) and Adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187. 2010. p 4-5. Available from: http://guidance.nice.org.uk/TA187.
91. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.
92. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Thomsen OO, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012;47:518-27.
93. Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010;32:1129-34.
94. Johnsen KM, Hansen V, Florholmen J, Goll R, Olsen T. Twelve years prospective study of infliximab treatment in ulcerative colitis performing and algorithm of repeated intensive induction therapies to remission and biomarkers for long term remission without need of infliximab [abstract]. United European Gastroenterol J 2014, 2 (1Suppl), A536.
95. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014;40:338-53.
96. Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol 2013;11:991-6.
97. Guanglin C, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: An approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006; 66:249-60.
98. Paulssen R, Goll R, Florholmen J. Towards a cure. Technology & Science, Pan European Network Ltd, Congleton, United Kingdom; 2014. p 178-9.